Cue Biopharma (CUE) Cantor Global Healthcare Conference 2025 summary

Recent clinical progress and data highlights

• Initiated two phase III trials (VANQUISH-1 and VANQUISH-2) for lead dual agonist VK2735 in obesity; both studies are progressing well with strong site and patient engagement.

• Phase II oral VK2735 study showed clear dose response, strong efficacy at top dose, and attractive tolerability, though high-dose AEs drew market attention; future development will focus on mid-range doses.

• Maintenance study will test both subcutaneous and oral regimens, including titration strategies and lower maintenance doses, with data expected mid next year.

• Amylin analog program advancing toward pre-IND meeting in Q4, with potential for both standalone and combination therapy with VK2735.

Development strategy and regulatory plans

• Next steps for oral VK2735 include full data analysis, end-of-phase II FDA meeting, and potential phase IIb or phase III initiation in the first half of next year.

• Dose selection for future studies will likely focus on 20–80 mg range, with titration and tablet size reduction to improve tolerability and retention.

• Discontinuation rates in obesity studies are a concern; strategies include offering placebo patients active drug in extension and enhanced patient engagement.

• Company is open to both subcutaneous and oral maintenance regimens, aiming for flexibility and long-term adherence.

Commercial and organizational outlook

• Company has doubled in size to 50+ employees, with further growth planned, especially in quality and operations, to support large-scale phase III trials.

• Commercialization strategy may blend a smaller sales force with a direct-to-patient online portal, leveraging lessons from the compounding market.

• Maintenance market for obesity drugs seen as a major opportunity, with payer feedback emphasizing the need for long-term therapy options.

• Cash-pay obesity market is expected to remain significant due to high demand and rapid market expansion.